Effects of Chestnuts on Postprandial Glycaemic Response

Not Applicable

Not yet recruiting

• Conditions: Postprandial Glycemia; Insulin Resistance

• Registration Number: NCT06960967
• Lead Sponsor: Monash University

Brief Summary

Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols.

Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-29
• Study First Submitted QC: 2025-04-29
• Last Update Submitted: 2025-04-29
• Study First Posted: 2025-05-07
• Last Update Posted: 2025-05-07
• Study Start: 2025-05-12
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Adults 18-65 years old
• Available to attend two testing sessions at the research facility

Exclusion Criteria

• Allergy to nuts and/or gluten,
• BMI<18.5 or ≥30 kg/m2,
• Fasting glucose >5.6 mmol/L, presence of diabetes and/or taking anti-diabetic medication
• Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery,
• Smoker,
• Cardiovascular disease
• Pregnant or breastfeeding women
• Presence of implanted cardiac defibrillator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Postprandial blood glucose incremental area under the curve (iAUC)	Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.	Difference in postprandial blood glucose iAUC
Postprandial plasma insulin incremental area under the curve (iAUC)	Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.	Difference in postprandial plasma insulin iAUC.

Secondary Outcome Measures

Name	Time	Method
Postprandial glucose concentration	Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.	Difference in postprandial glucose concentration
Postprandial insulin concentration	Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.	Difference in postprandial insulin concentration
Time to peak glucose	Three hours	Difference in time to peak glucose